Pfizer: Vaccine 90% effective in Phase 3 trialPfizer said the vaccine was a 'much needed breakthrough' in the fight against Covid-19. (AFP photo)PARIS: A vaccine jointly developed by Pfizer and BioNTech was 90% effective in preventing Covid-19 infections in ongoing Phase 3 trials, the companies announced Monday. "The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent Covid-19," Pfizer chairman and CEO Albert Bourla said in a statement. Two Russian Covid-19 vaccines have been registered for us even before clinical trials were completed, but have not been widely accepted outside of Russia. Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.

Source: Bangkok Post November 09, 2020 12:45 UTC